Artiva Biotherapeutics Pauses Phase 3 Trial Following Patient Death
Artiva Biotherapeutics has paused enrollment and dosing in its Phase 3 clinical trial at the request of the FDA following a patient death.
Stocks · News reference
Artiva Biotherapeutics Discontinues Development of Lead Candidate AlloNK and Initiates Strategic Review
Artiva Biotherapeutics has decided to halt the development of its lead product candidate, AlloNK, and is exploring strategic alternatives to maximize stockholder value.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies
Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
Jefferies Downgrades Artiva Biotherapeutics to Hold
Jefferies has downgraded Artiva Biotherapeutics from Buy to Hold, setting a price target of $4 per share.
Artiva Biotherapeutics Announces Workforce Reduction and Strategic Alternatives Review
Artiva Biotherapeutics is laying off 94% of its workforce and evaluating strategic alternatives following the death of two patients in a Phase IIa clinical trial.
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
Artiva Biotherapeutics ends its AlloNK program after fatal safety events, slashes 94% of its workforce, and weighs strategic liquidation.
8-K filing — Artiva Biotherapeutics, Inc. (ARTV)
Filed: 2026-10-27 AccNo: 0001193125-26-432806 Size: 178 KB Item 2.02: Results of Operations and Financial Condition Item 2.05: Cost Associated with Exit or Disposal Activities Item 9.01: Financial Statements and Exhibits